Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$235.3 million.

  • Kymera Therapeutics' Cash from Investing Activities fell 4922.56% to -$235.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.1 million, marking a year-over-year increase of 8719.51%. This contributed to the annual value of -$404.1 million for FY2024, which is 38886.16% down from last year.
  • As of Q3 2025, Kymera Therapeutics' Cash from Investing Activities stood at -$235.3 million, which was down 4922.56% from $60.0 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Cash from Investing Activities peaked at $81.8 million during Q2 2022, and registered a low of -$330.6 million during Q1 2024.
  • In the last 5 years, Kymera Therapeutics' Cash from Investing Activities had a median value of $24.6 million in 2023 and averaged -$24.7 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 160473.68% in 2021, then surged by 28371.69% in 2025.
  • Kymera Therapeutics' Cash from Investing Activities (Quarter) stood at -$68.0 million in 2021, then grew by 26.98% to -$49.7 million in 2022, then surged by 138.16% to $19.0 million in 2023, then skyrocketed by 261.8% to $68.6 million in 2024, then tumbled by 443.16% to -$235.3 million in 2025.
  • Its Cash from Investing Activities stands at -$235.3 million for Q3 2025, versus $60.0 million for Q2 2025 and $48.6 million for Q1 2025.